Sinopsys Surgical sniffs up $8.3m for sinusitis device

Stealth-mode startup Sinopsys Surgical reports an $8.3 million funding round for the sinusitis drug-device treatment it's developing.

Stealth-mode startup Sinopsys Surgical said it raised $8.3 million in an equity funding round for the technique it's developing to repurpose the tear duct to drain into the sinuses as a way to relieve chronic sinusitis.

CEO Dr. Harry Ross was a partner with Aweida Venture Partners of Superior, Colo., near to Sinopsys Surgical's Boulder headquarters.

Sinopsys Surgical

News Well, Funding Roundup, Optical/Ophthalmic, Venture Capital/Private Equity

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1uh17Hs